We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc
RUBY

Delisted

RUBY was delisted on the 6th of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Rubius Therapeutics, Inc in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $61.3K → $0 (-$61.3K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
–
Holders Change
-7
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$44K
2
SOMRS
State of Michigan Retirement System
Michigan
-$13.6K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2K
4
BBA
Baader Bank Aktiengesellschaft
Germany
-$1.22K
5
CGL
Clarius Group LLC
Washington
-$456
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
– -$44K -2,042,666 Closed
SOMRS
2
State of Michigan Retirement System
Michigan
– -$13.6K -640,000 Closed
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
– -$2K -179,676 Closed
BBA
4
Baader Bank Aktiengesellschaft
Germany
– -$1.22K -73,420 Closed
CGL
5
Clarius Group LLC
Washington
– -$456 -21,393 Closed

RUBY Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2023, worth a combined $0 — down 100% from $61.3K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RUBY and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Artal Group, exiting entirely with an estimated $44K sold.

  • 0 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2023, down from 7 in Q1 2023.
  • Funds reported $0 of Rubius Therapeutics, Inc stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Rubius Therapeutics, Inc positions in Q2 2023 and 7 closed out, a net change of -7 holders.
  • The largest Rubius Therapeutics, Inc seller in Q2 2023 was Artal Group, an estimated $44K sold.

Based on aggregated 13F filings for Q2 2023.